Loading...
Anti-CD19 CAR T-cell therapy is potentially curative for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), although long-term outcomes are incompletely understood. Investigators report updated, 5-year results of a multicenter retrospective analysis of axicabtagene ciloleucel (axi-cel) therapy in 275 patients who had received at least two prior lines of therapy. Bridging therapy was allowed prior to CAR T-cell administration; 43% of patients would not have been eligible for the registrational clinical trial that led to FDA approval of axi-cel.
Findings at a median follow-up of 58 months were as follows:
The overall response rate was 82%, with complete response in 64%; three early deaths were related to CAR T-cell–associate…